Dabigatran etexilate Orion: Uses, Dosage & Side Effects
A direct oral anticoagulant (DOAC) that prevents blood clots by directly inhibiting thrombin, used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism
Dabigatran etexilate Orion is a direct oral anticoagulant (DOAC) belonging to the class of direct thrombin inhibitors. It is a generic version of the well-established medicine Pradaxa. The active substance, dabigatran etexilate, is a prodrug that is converted to dabigatran in the body. Dabigatran works by directly and reversibly blocking the activity of thrombin (factor IIa), a key enzyme in the blood clotting cascade. It is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat and prevent recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent venous thromboembolism after elective hip or knee replacement surgery. Dabigatran etexilate Orion offers the advantage of fixed dosing without routine coagulation monitoring, and a specific reversal agent (idarucizumab) is available for emergency situations.
Quick Facts: Dabigatran etexilate Orion
Key Takeaways
- Dabigatran etexilate Orion is a direct oral anticoagulant (DOAC) that works by directly inhibiting thrombin, preventing blood clot formation without the need for routine INR monitoring required with warfarin.
- It is primarily prescribed for stroke prevention in adults with non-valvular atrial fibrillation, for treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), and for VTE prevention after hip or knee replacement surgery.
- The capsules must be swallowed whole and never opened, crushed, or chewed, as this dramatically increases bioavailability and the risk of serious bleeding by approximately 75%.
- Kidney function must be assessed before starting treatment and monitored regularly, as approximately 80% of dabigatran is excreted by the kidneys; the drug is contraindicated in severe renal impairment (CrCl < 30 mL/min).
- A specific reversal agent, idarucizumab (Praxbind), is available for emergency situations involving life-threatening bleeding or urgent surgery, providing immediate and complete reversal of dabigatran’s anticoagulant effect.
What Is Dabigatran etexilate Orion and What Is It Used For?
Dabigatran etexilate Orion contains the active substance dabigatran etexilate, which belongs to a class of medicines known as direct oral anticoagulants (DOACs), sometimes also referred to as novel oral anticoagulants (NOACs). Unlike older anticoagulants such as warfarin, which act indirectly by inhibiting the synthesis of several clotting factors in the liver, dabigatran works by directly and specifically targeting a single enzyme in the coagulation cascade: thrombin (also called coagulation factor IIa). This direct mechanism of action provides a more predictable anticoagulant effect and eliminates the need for routine laboratory monitoring of blood clotting levels.
Dabigatran etexilate is a prodrug, meaning it is not pharmacologically active in its ingested form. After oral administration, it is rapidly absorbed from the gastrointestinal tract and converted to its active form, dabigatran, by esterase-mediated hydrolysis in the plasma and liver. The active metabolite, dabigatran, is a potent, competitive, and reversible direct thrombin inhibitor. Thrombin is a serine protease that plays a central role in the coagulation cascade: it converts soluble fibrinogen into insoluble fibrin strands that form the structural framework of a blood clot, activates platelets, and amplifies its own production through positive feedback mechanisms. By blocking thrombin, dabigatran effectively interrupts these processes and prevents the formation and growth of pathological blood clots.
Importantly, dabigatran inhibits both free thrombin (circulating in the blood) and fibrin-bound thrombin (already incorporated within an existing clot), as well as thrombin-induced platelet aggregation. This comprehensive inhibition profile contributes to its clinical efficacy across multiple thrombotic conditions. The anticoagulant effect of dabigatran is directly proportional to its plasma concentration, providing a predictable dose-response relationship that allows for fixed dosing without the variability and monitoring requirements associated with vitamin K antagonists.
Dabigatran etexilate Orion is a generic formulation that contains the same active substance and has been demonstrated to be bioequivalent to the originator product Pradaxa. It is approved by regulatory authorities including the European Medicines Agency (EMA) for the following indications:
- Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF): Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting millions of people worldwide. In AF, the upper chambers of the heart (atria) beat irregularly and often rapidly, which can cause blood to pool and form clots. These clots may travel to the brain and cause a stroke, or to other organs causing systemic embolism. Dabigatran significantly reduces this risk. The landmark RE-LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin in preventing stroke and systemic embolism, while dabigatran 110 mg twice daily was non-inferior to warfarin with a significantly lower rate of major bleeding.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults: Deep vein thrombosis occurs when a blood clot forms in a deep vein, usually in the leg, causing pain, swelling, and potentially life-threatening complications. Pulmonary embolism occurs when a clot (or part of a clot) breaks loose and travels to the lungs, blocking blood flow. Dabigatran is used for the ongoing treatment of these conditions after an initial period (at least 5 days) of treatment with an injectable anticoagulant (such as heparin or enoxaparin). The RE-COVER trials demonstrated that dabigatran was non-inferior to warfarin for treating acute VTE with a significantly lower rate of major or clinically relevant non-major bleeding.
- Prevention of venous thromboembolism (VTE) in adults who have undergone elective hip replacement surgery or knee replacement surgery: Major orthopedic surgery carries a high risk of blood clot formation in the deep veins of the legs. Without preventive treatment (thromboprophylaxis), the incidence of VTE after hip and knee surgery can be as high as 40–60%. Dabigatran is started after surgery (once hemostasis has been achieved) and continued for a defined period to reduce this risk. The RE-MODEL, RE-MOBILIZE, and RE-NOVATE trials established its efficacy and safety in this setting.
Dabigatran etexilate Orion must not be used in patients with prosthetic (mechanical) heart valves. The RE-ALIGN trial, which evaluated dabigatran in patients with mechanical heart valves, was terminated early due to an excess of thromboembolic events and bleeding. Patients with mechanical heart valves should continue to use warfarin or other vitamin K antagonists as recommended by their cardiologist.
The pharmacokinetic profile of dabigatran is well characterized. After oral administration, peak plasma concentrations are reached within 0.5 to 2 hours. The oral bioavailability is approximately 6.5%, which is consistent across individuals. The terminal elimination half-life averages 12 to 17 hours in healthy volunteers, allowing for twice-daily dosing. A crucial feature of dabigatran’s pharmacology is that approximately 80% of the drug is excreted unchanged by the kidneys, making renal function a critical determinant of drug exposure and bleeding risk. This is why kidney function assessment is mandatory before treatment initiation and must be monitored throughout therapy.
What Should You Know Before Taking Dabigatran etexilate Orion?
Contraindications
There are specific situations in which dabigatran etexilate Orion must not be used. Understanding these absolute contraindications is essential for patient safety.
- Hypersensitivity: Do not take dabigatran etexilate Orion if you are allergic to dabigatran etexilate, dabigatran, or any of the other ingredients in the capsules.
- Severe renal impairment: Dabigatran is contraindicated in patients with a creatinine clearance (CrCl) below 30 mL/min. Since approximately 80% of the drug is eliminated by the kidneys, severe renal impairment leads to dangerous accumulation of the drug and significantly increased bleeding risk.
- Active clinically significant bleeding: The medicine must not be started or continued in patients who are currently experiencing serious bleeding, such as gastrointestinal hemorrhage, intracranial bleeding, or other significant hemorrhage.
- Lesions or conditions with significant risk of major bleeding: This includes conditions such as current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, or vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
- Concurrent treatment with other anticoagulants: Dabigatran must not be used simultaneously with unfractionated heparin, low molecular weight heparins, heparin derivatives, other oral anticoagulants (warfarin, rivaroxaban, apixaban, edoxaban), or any systemic anticoagulant, except during the transition between anticoagulant therapies or when heparin is given at doses needed to maintain a central venous or arterial catheter.
- Hepatic impairment or liver disease expected to impact survival: Patients with severe liver disease, including those with elevated liver enzymes more than twice the upper limit of normal, should not take dabigatran.
- Concurrent treatment with systemic ketoconazole, cyclosporine, itraconazole, dronedarone, and the fixed-dose combination of glecaprevir/pibrentasvir: These drugs are strong inhibitors of P-glycoprotein (P-gp) and significantly increase dabigatran plasma levels, leading to unacceptable bleeding risk.
- Prosthetic heart valves: Dabigatran must not be used in patients with mechanical heart valves requiring anticoagulant treatment, as clinical trial data showed an unacceptable risk of thromboembolic complications.
Warnings and Precautions
Like all anticoagulants, dabigatran etexilate Orion can cause serious and potentially life-threatening bleeding. Seek immediate medical attention if you experience signs of significant bleeding: prolonged or unexplained bruising, pink or brown urine, red or black (tarry) stools, coughing up blood, vomiting blood or material that looks like coffee grounds, unexplained persistent nosebleeds, unusual gum bleeding, or if bleeding from a cut does not stop. A specific reversal agent, idarucizumab (Praxbind), is available for emergency reversal of dabigatran.
Before and during treatment with dabigatran etexilate Orion, the following precautions should be considered:
- Renal function monitoring: Kidney function must be assessed before starting treatment by calculating creatinine clearance (CrCl) using the Cockcroft-Gault formula. Renal function should then be reassessed at least once a year, or more frequently in situations where renal decline is suspected (such as hypovolemia, dehydration, concomitant use of certain medications, or in elderly patients). If CrCl falls below 30 mL/min during treatment, dabigatran must be discontinued.
- Age-related considerations: Patients aged 75 years and older are at increased risk of bleeding. For patients 80 years and older with atrial fibrillation, the recommended dose is 110 mg twice daily. Elderly patients should have their renal function monitored more frequently.
- Surgery and invasive procedures: Dabigatran must be temporarily stopped before surgery or invasive procedures. The duration of interruption depends on the type of procedure (standard vs. high bleeding risk) and the patient’s renal function. For standard-risk procedures, the last dose should be taken at least 24 hours before (or 48 hours in patients with CrCl 30–50 mL/min). For high-risk procedures, the last dose should be taken at least 48 hours before (or 96 hours in patients with CrCl 30–50 mL/min). Treatment should be restarted as soon as adequate hemostasis is achieved.
- Spinal/epidural anesthesia or puncture: There is a risk of spinal or epidural hematoma, which can lead to long-term or permanent paralysis. If a traumatic or repeated spinal puncture occurs, delaying dabigatran administration for 24 hours should be considered. An epidural catheter should not be removed until at least 6 hours after the last dose of dabigatran, and the next dose should be given no sooner than 6 hours after catheter removal.
- Body weight: Limited clinical data exist for patients weighing less than 50 kg or more than 110 kg. While no dose adjustment is specifically recommended, these patients should be monitored closely.
- Gastrointestinal bleeding: Dabigatran may be associated with a higher risk of gastrointestinal (GI) bleeding compared with warfarin, particularly at the 150 mg twice-daily dose. This risk is greatest in the first 3–6 months of therapy. Patients with a history of GI bleeding, active GI ulcer disease, or other gastrointestinal conditions predisposing to hemorrhage should be treated with caution.
- Dyspepsia: Gastrointestinal symptoms including dyspepsia, gastritis-like symptoms, and abdominal discomfort are among the most common side effects. These are attributed to the tartaric acid core of the capsule formulation. Taking the capsules with food or a full glass of water may help alleviate these symptoms.
Pregnancy and Breastfeeding
Dabigatran etexilate Orion should not be used during pregnancy unless clearly necessary. There is limited human data on the use of dabigatran in pregnant women. Animal studies have shown reproductive toxicity, including decreased fetal viability and increased fetal variations at doses that also caused maternal toxicity. The potential risk to the human fetus is unknown, and the use of dabigatran during pregnancy should be avoided unless the potential benefit is considered to outweigh the risk to the fetus.
Women of childbearing potential should avoid pregnancy during treatment with dabigatran etexilate Orion. Effective contraception should be used throughout treatment. If you become pregnant during treatment, contact your doctor immediately to discuss whether the benefit of continuing therapy outweighs the potential risk.
It is not known whether dabigatran is excreted in human breast milk. No clinical data are available on the effect of dabigatran on breastfed infants. As a precautionary measure, breastfeeding should be discontinued during treatment with dabigatran etexilate Orion. Your doctor will advise you on the best approach.
Driving and Operating Machinery
Dabigatran etexilate Orion has no known direct effect on the ability to drive or operate machinery. However, as with any anticoagulant, patients should be aware that bleeding events can occur unexpectedly, and these may indirectly affect the ability to perform tasks requiring concentration and physical coordination.
How Does Dabigatran etexilate Orion Interact with Other Drugs?
Drug interactions with dabigatran etexilate primarily involve the P-glycoprotein (P-gp) transport system. Dabigatran etexilate (the prodrug) is a substrate of the P-gp efflux transporter, which is expressed in the intestinal epithelium, hepatocytes, renal tubular cells, and other tissues. P-gp acts as a barrier, pumping the drug back into the intestinal lumen and reducing its absorption. Medications that inhibit or induce P-gp can therefore significantly alter the plasma levels of dabigatran, potentially affecting both efficacy and safety. Unlike many other drugs, dabigatran is not metabolized by cytochrome P450 (CYP) enzymes to a clinically relevant extent, which means it has fewer interactions through the CYP pathway compared with other anticoagulants.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor; increases dabigatran AUC by approximately 140–150% | Contraindicated – never combine |
| Dronedarone | Strong P-gp inhibitor; increases dabigatran exposure by approximately 70–100% | Contraindicated – never combine |
| Itraconazole, Cyclosporine | Strong P-gp inhibitors; significantly increase dabigatran levels | Contraindicated – never combine |
| Glecaprevir/pibrentasvir | P-gp inhibitors; increase dabigatran exposure | Contraindicated – never combine |
| Other anticoagulants (warfarin, heparin, LMWH, rivaroxaban, apixaban) | Additive anticoagulant effect; substantially increased bleeding risk | Contraindicated – do not combine (except during transition) |
| Rifampicin | Strong P-gp inducer; decreases dabigatran AUC by approximately 66% | Avoid – significantly reduces efficacy, risk of thrombosis |
Clinically Significant Interactions Requiring Dose Adjustment or Caution
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Verapamil | P-gp inhibitor; increases dabigatran AUC by 12–180% depending on timing and formulation | Reduce dose to 110 mg twice daily for AF; take dabigatran at least 2 hours before verapamil |
| Amiodarone | P-gp inhibitor; increases dabigatran AUC by approximately 50–60% | No dose reduction generally needed, but close monitoring advised; consider 110 mg BID in high-risk patients |
| Quinidine | P-gp inhibitor; increases dabigatran levels | Use with caution; monitor for bleeding |
| Ticagrelor | P-gp inhibitor; increases dabigatran exposure by approximately 65–75% | Use with caution; increased bleeding risk |
| Acetylsalicylic acid (ASA/aspirin) | Antiplatelet effect; additive bleeding risk without altering dabigatran levels | Increased bleeding risk; use only when clearly indicated |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Antiplatelet effect and GI mucosal damage; additive bleeding risk | Avoid long-term use; increased GI bleeding risk |
| SSRIs/SNRIs | Impair platelet function; additive bleeding risk | Monitor for increased bleeding, especially GI |
| St John’s wort (Hypericum perforatum) | P-gp inducer; reduces dabigatran levels | Avoid concomitant use; reduced anticoagulant efficacy |
| Carbamazepine, Phenytoin | P-gp inducers; may reduce dabigatran levels | Use with caution; monitor for reduced efficacy |
| Proton pump inhibitors (PPIs) | May reduce dabigatran absorption by approximately 20–30% | No dose adjustment needed; considered clinically insignificant |
Always inform your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, herbal remedies, and dietary supplements. Particular care is needed when combining dabigatran with any drug that affects hemostasis (blood clotting) or P-glycoprotein transport. Your doctor will assess whether dose adjustments or alternative treatment strategies are needed based on the specific drug combinations involved.
What Is the Correct Dosage of Dabigatran etexilate Orion?
The dose of dabigatran etexilate Orion depends on the indication for which it is prescribed, the patient’s age, kidney function, body weight, and concomitant medications. Always take this medicine exactly as your doctor has told you. The capsules should be swallowed whole with a full glass of water and may be taken with or without food. Do not open, crush, or chew the capsules.
Stroke Prevention in Atrial Fibrillation
Standard Adult Dose
Dose: 150 mg twice daily (one capsule in the morning and one in the evening, approximately 12 hours apart)
Duration: Long-term (usually lifelong or until the indication no longer exists)
This dose was shown to be superior to warfarin for stroke prevention in the RE-LY trial, with a relative risk reduction of 35% for stroke and systemic embolism.
Reduced Dose – 110 mg Twice Daily
Recommended for:
- Patients aged 80 years and older
- Patients concomitantly taking verapamil (take dabigatran at least 2 hours before verapamil)
To be considered for:
- Patients aged 75–80 years
- Patients with moderate renal impairment (CrCl 30–50 mL/min)
- Patients with gastritis, esophagitis, or gastroesophageal reflux
- Other patients at increased risk of bleeding
Treatment of DVT and PE, and Prevention of Recurrence
Adult Dose
Dose: 150 mg twice daily
Prerequisites: Treatment must follow at least 5 days of initial parenteral anticoagulation (such as heparin, enoxaparin, or fondaparinux)
Duration: At least 3 months for treatment of acute DVT/PE. Extended therapy (6–12 months or longer) may be recommended based on individual risk assessment, including the balance between the risk of recurrent VTE and the risk of bleeding.
A reduced dose of 110 mg twice daily should be considered for patients aged 80 years or older or those concomitantly taking verapamil.
VTE Prevention After Hip or Knee Replacement Surgery
Standard Dose
Dose: 220 mg once daily (taken as two 110 mg capsules together)
First dose: 110 mg (one capsule), taken 1–4 hours after surgery, once hemostasis is achieved
Duration:
- Hip replacement: 28–35 days
- Knee replacement: 10 days
Reduced Dose – 150 mg Once Daily
Recommended for:
- Patients with moderate renal impairment (CrCl 30–50 mL/min)
- Patients aged 75 years and older
- Patients concomitantly taking amiodarone, quinidine, or verapamil
First dose: 75 mg, taken 1–4 hours after surgery
Children
The safety and efficacy of dabigatran etexilate Orion in children and adolescents below 18 years of age have not been established for the capsule formulation. Pediatric formulations (oral pellets or solution) of the originator product may be available for certain pediatric indications, but these are distinct from the adult capsule formulation. Do not give dabigatran etexilate Orion capsules to children.
Missed Dose
If you miss a dose, take it as soon as you remember, provided there are still at least 6 hours before the next scheduled dose. If less than 6 hours remain until the next dose, skip the missed dose and take the next dose at the regular scheduled time. Do not take a double dose to make up for a forgotten one. Never take two doses at the same time. If you are unsure about what to do, contact your doctor or pharmacist.
Overdose
If you take more dabigatran etexilate Orion than prescribed, seek immediate medical attention. There is no specific oral antidote that you can take at home. However, in a hospital setting, the specific reversal agent idarucizumab (Praxbind) can be administered intravenously to immediately and completely reverse the anticoagulant effect of dabigatran. Additional measures may include the use of activated charcoal (if ingestion was within the last 2 hours), surgical hemostasis, volume replacement, and in severe cases, hemodialysis (dabigatran is dialyzable, with approximately 60% removed during 4 hours of dialysis).
Dabigatran etexilate Orion capsules must be swallowed whole. Do not open, crush, break, or chew the capsules. Removing the capsule shell and taking the pellets alone increases the oral bioavailability by approximately 75%, dramatically increasing the risk of serious and potentially life-threatening bleeding.
What Are the Side Effects of Dabigatran etexilate Orion?
Like all medicines, dabigatran etexilate Orion can cause side effects, although not everyone gets them. The most clinically significant side effect is bleeding, which is an expected pharmacological consequence of all anticoagulant medications. The risk and severity of bleeding depend on multiple factors, including the dose, patient age, kidney function, body weight, concomitant medications, and underlying conditions. Your medical team will carefully weigh the benefits of anticoagulation against the bleeding risk for your individual situation.
Very Common
May affect more than 1 in 10 people
- Decreased hemoglobin (reduction in the oxygen-carrying protein in red blood cells, detected on blood tests)
Common
May affect up to 1 in 10 people
- Nosebleed (epistaxis)
- Gastrointestinal bleeding (which may present as blood in stools, black or tarry stools, or vomiting blood)
- Abdominal pain, stomach discomfort, or indigestion (dyspepsia)
- Nausea
- Diarrhea
- Gastritis-like symptoms (inflammation of the stomach lining)
- Gastroesophageal reflux (heartburn)
- Urogenital bleeding (blood in urine, heavier menstrual periods)
- Skin bleeding (bruising, hematoma at injection sites or wound sites)
- Anemia (low red blood cell count)
- Abnormal liver function tests
Uncommon
May affect up to 1 in 100 people
- Intracranial hemorrhage (bleeding inside the skull, a serious and potentially life-threatening event)
- Hemoptysis (coughing up blood)
- Rectal bleeding
- Hemorrhoidal bleeding
- Gastrointestinal ulceration, including esophageal ulcer
- Hypersensitivity reactions (rash, itching, allergic skin reactions)
- Urticaria (hives)
- Thrombocytopenia (low platelet count)
- Dysphagia (difficulty swallowing)
- Wound bleeding or post-procedural hemorrhage
Rare
May affect up to 1 in 1,000 people
- Anaphylactic reaction (severe, life-threatening allergic reaction)
- Angioedema (swelling of the face, lips, tongue, throat, or other body areas)
- Bronchospasm (tightening of the airways)
- Surgical site hemorrhage
- Retroperitoneal bleeding
- Intra-articular bleeding (bleeding into a joint)
- Intramuscular bleeding (bleeding into muscle tissue)
Not Known
Frequency cannot be estimated from available data
- Esophagitis (inflammation of the esophagus)
- Gastroesophageal erosion
Contact your doctor or go to the nearest emergency department immediately if you experience any of the following: signs of major bleeding (such as blood in urine, vomit, or stools; coughing up blood; severe bruising; prolonged bleeding from cuts), symptoms of stroke (sudden numbness or weakness, confusion, trouble speaking, severe headache, vision changes), or signs of a severe allergic reaction (difficulty breathing, swelling of face or throat, severe rash).
The risk of intracranial hemorrhage is notably lower with dabigatran compared with warfarin – this was a consistent finding across the RE-LY and subsequent real-world studies. In the RE-LY trial, the rate of intracranial hemorrhage was 0.30% per year with dabigatran 150 mg twice daily and 0.23% per year with 110 mg twice daily, compared with 0.74% per year with warfarin (a relative risk reduction of 59–69%). However, the rate of gastrointestinal bleeding was higher with dabigatran 150 mg twice daily (1.51% per year) compared with warfarin (1.02% per year). The 110 mg twice-daily dose had a similar GI bleeding rate to warfarin.
If you experience any side effects, including those not listed here, tell your doctor or pharmacist. You can also report suspected side effects directly to your national pharmacovigilance authority (e.g., the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom) to help monitor the ongoing safety profile of this medicine.
How Should You Store Dabigatran etexilate Orion?
Proper storage of dabigatran etexilate Orion is important to ensure the medicine remains effective and safe throughout its shelf life. The capsules are particularly sensitive to moisture, which can affect the stability and bioavailability of the active substance.
- Temperature: Do not store above 30°C (86°F). Store at room temperature.
- Moisture protection: Keep the capsules in their original blister packaging or bottle with the desiccant cap. The desiccant absorbs moisture and should not be removed from the bottle.
- Bottles: Once the bottle has been opened, the capsules must be used within 4 months. Close the bottle tightly after each use to protect from moisture.
- Blister packs: Peel back the foil backing to remove each capsule. Do not push the capsules through the blister foil, as this may damage the capsule shell.
- Do not transfer: Do not place the capsules in pill boxes, pill organizers, or other containers. This exposes them to moisture and may compromise the medication’s integrity.
- Keep out of reach of children: Store in a safe place where children cannot access the medicine.
- Expiry date: Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.
What Does Dabigatran etexilate Orion Contain?
Active Substance
The active substance is dabigatran etexilate (as dabigatran etexilate mesilate). Each hard capsule contains dabigatran etexilate mesilate equivalent to 75 mg, 110 mg, or 150 mg of dabigatran etexilate. Dabigatran etexilate is a prodrug that has no pharmacological activity in its own right; after oral absorption, it is rapidly and completely converted to dabigatran, the active direct thrombin inhibitor, by esterase-catalyzed hydrolysis in the plasma and liver.
Inactive Ingredients (Excipients)
The capsule contents include:
- Tartaric acid – a key excipient that creates an acidic microenvironment to enhance absorption of dabigatran etexilate, which is poorly soluble at neutral pH
- Acacia (gum arabic)
- Hypromellose (HPMC)
- Dimeticone (simethicone)
- Talc
- Hydroxypropylcellulose
The capsule shell is composed of hypromellose (HPMC) and additional standard pharmaceutical excipients including colorants such as titanium dioxide (E171), iron oxide yellow (E172), and potentially indigo carmine (E132) or iron oxide red (E172), depending on the capsule strength and appearance.
Appearance
Dabigatran etexilate Orion hard capsules contain yellowish pellets within a hypromellose capsule shell. The capsule color and markings vary by strength to help distinguish between the 75 mg, 110 mg, and 150 mg doses. The capsules are supplied in blister packs or bottles with a moisture-absorbing desiccant cap.
Manufacturer
Dabigatran etexilate Orion is manufactured and marketed by Orion Corporation, a Finnish pharmaceutical company. The product is authorized as a generic medicine based on demonstrated bioequivalence with the originator product Pradaxa (manufactured by Boehringer Ingelheim), which was the first direct thrombin inhibitor approved for oral anticoagulation and has accumulated extensive clinical experience since its initial approval in 2008.
Frequently Asked Questions About Dabigatran etexilate Orion
Dabigatran etexilate Orion is used for three main indications: (1) prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation who have one or more risk factors for stroke, (2) treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, and (3) prevention of venous thromboembolism in adults who have undergone elective hip or knee replacement surgery. It is a blood-thinning medication that works by directly blocking thrombin, a key enzyme in the blood clotting process.
Dabigatran offers several advantages over warfarin: it has a predictable dose-response that eliminates the need for routine INR blood testing, reaches therapeutic levels within hours (compared with days for warfarin), has fewer food interactions, and has a specific reversal agent (idarucizumab/Praxbind). In clinical trials, dabigatran 150 mg twice daily was superior to warfarin for stroke prevention and had a significantly lower rate of intracranial hemorrhage. However, warfarin remains the preferred anticoagulant for patients with mechanical heart valves, and some patients may still be better managed with warfarin based on their individual clinical profile.
Yes, dabigatran etexilate Orion capsules can be taken with or without food. Food does not significantly affect the total amount of drug absorbed, although it may delay the time to peak plasma concentration by approximately 2 hours. Taking the capsules with food or a full glass of water may help reduce gastrointestinal side effects such as dyspepsia and stomach discomfort, which are among the most common complaints with this medication. The capsules must be swallowed whole – never open, crush, or chew them.
If you miss a dose of dabigatran etexilate Orion, take it as soon as you remember, but only if there are at least 6 hours remaining before your next scheduled dose. If there are fewer than 6 hours until the next dose, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to make up for one you forgot. Missing doses increases the risk of blood clot formation, so try to take the medication consistently at the same times each day. If you frequently forget doses, discuss strategies with your doctor or pharmacist.
Yes. Idarucizumab (Praxbind) is a specific reversal agent for dabigatran that was approved in 2015. It is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with extremely high affinity (approximately 350 times greater than dabigatran’s affinity for thrombin), neutralizing its anticoagulant effect within minutes. Idarucizumab is given intravenously (5 g total, as two consecutive infusions) in hospital emergency settings for life-threatening or uncontrolled bleeding, or when urgent surgery or invasive procedures are required. The RE-VERSE AD study demonstrated that idarucizumab provided complete reversal of dabigatran in the vast majority of patients within minutes.
Dabigatran can be used in elderly patients, but dose adjustments are necessary. For patients aged 80 years and older with atrial fibrillation, the recommended dose is 110 mg twice daily instead of 150 mg twice daily. Elderly patients are at increased risk of bleeding due to age-related decline in kidney function, frailty, and common concomitant use of other medications that increase bleeding risk. Renal function should be monitored at least annually, and more frequently in patients aged 75 or older. Your doctor will carefully balance the benefits of stroke prevention against the bleeding risk.
References
- European Medicines Agency (EMA). Dabigatran etexilate – Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561.
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER). N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598.
- Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612.
- U.S. Food and Drug Administration (FDA). Pradaxa (dabigatran etexilate mesylate) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement (RE-NOVATE II). Thromb Haemost. 2011;105(4):721–729. doi:10.1160/TH10-10-0679.
- Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272–1274. doi:10.1056/NEJMp1302834.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Atrial fibrillation: diagnosis and management. NICE guideline NG196. Updated 2024.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in cardiology, hematology, and clinical pharmacology.
Medical Content
iMedic Cardiology Editorial Team – specialist physicians in cardiology and internal medicine with clinical experience in anticoagulation management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, ESC, and ISTH guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and anticoagulant safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.